** Shares of Australian Clinical Labs ACL.AX fall 18.9% to A$3, their lowest level since August 30, 2024

** Pathology services provider posts HY underlying NPAT of A$12.1 million ($7.68 million), below Visible Alpha consensus of A$15.5 million

** Co say it's on track to deliver FY25 underlying EBIT guidance in range of A$65 million to A$73 million, mid-point of which is lower than Visible Alpha consensus of A$71 million

** 1.1 million shares change hands, 2.1x the 30-day average of 527,734

** Stock down 12.8% YTD, including session's moves

($1 = 1.5748 Australian dollars)

(Reporting by Jasmeen Ara Shaikh in Bengaluru)

((Jasmeenaraislam.shaikh@thomsonreuters.com))